我的购物车

NF-κB (Luc) HEK293 Reporter Cell

用户评价
货号-规格
价格
Qty.

CHEK-ATF048-2Vials (1Vial X 2)
询价
合计0件 产品金额$ 0
0
加入购物车

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    The NF-kB (Luc) HEK293 Reporter Cell was engineered with the NF-kB response element driving luciferase expressing systems. The receptors expressing endogenously or transfected on this reporter cell were activated by corresponding ligands binding, transducing intracellular signals resulting in NF-kB-RE mediated luminescence.

  • 应用说明(Application)

    • The discovery of activators or inhibitors by the NF-kB signaling bioactivity

    • Transfection host for some receptors concerning the NF-kB signaling pathway

    NF-κB Assay Principles

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Puromycin (2 μg/mL)

  • 培养基(Complete Growth Medium)

    DMEM medium + 10% FBS

  • 冻存液(Freeze Medium)

    Serum-free cell cryopreservation medium

  • 装量(Quantity)

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • Signaling Bioassay

     NF-κB SIGNALING

    Response to human TNFα protein (RLU).
    The NF-kB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TNFα protein (Cat. No. TNA-H4211). The EC50 was approximately 0.64 ng/mL.

    Protocol
  •  NF-κB SIGNALING

    Response to human TNFα protein (FOLD).
    The NF-kB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TNFα protein (Cat. No. TNA-H4211). The max induction fold was approximately 235.

    Protocol
  • Passage Stability

     NF-κB PASSAGE

    Passage stability analysis by Signaling Bioassay.
    The continuously growing NF-kB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TNFα protein (Cat. No. TNA-H4211). Human TNFα protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 8-26.

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

重要声明

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

前沿进展

 
药物研发进展
  • 英文全称:

    Nuclear factor NF-kappa-B complex

  • 中文全称:

    核因子NF-κB复合体

  • 种类:

  • 上市药物数量:

    11 详情

  • 临床药物数量:

    40 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 重要声明